184698-41-7

Basic information

• Product Name: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)
• Synonyms: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI);4-Aminotetrahydropyran-4-carboxylic acid methyl ester;Methyl 4-aminotetrahydropyran-4-carboxylate hydrochloride , 95%;Methyl 4-aMinotetrahydro-2H-pyran-4-carboxylate;4-AMinotetrahydro-2H-pyran-4-carboxylic acid Methyl ester;Methyl 4-aMinotetrahydro-2H-pyran-4-carboxylate hydrochloride;Methyl 4-AMinotetrahydropyran-4-carboxylate;methyl 4-aminooxane-4-carboxylate
• CAS NO: 184698-41-7
• Molecular Formula: C₇H₁₃NO₃
• Molecular Weight: 159.184
• Product Categories: CARBOXYLICESTER;pharmacetical
• Mol File: 184698-41-7.mol

Chemical Properties

• Boiling Point: 223.5°Cat760mmHg
• Flash Point: 87.8°C
• Appearance: /
• Density: 1.128g/cm³
• Vapor Pressure: 0.096mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 6.24±0.20(Predicted)
• CAS DataBase Reference: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)(184698-41-7)
• EPA Substance Registry System: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)(184698-41-7)

Safety Data

• Hazardous Substances Data: 184698-41-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2H-Pyran-4-carboxylic acid, 4-aminotetrahydro-, methyl ester (9CI) is used as a building block for the synthesis of other organic compounds. Its chemical properties allow it to be a key intermediate in the creation of a wide range of molecules, contributing to the development of new materials and compounds in the chemical industry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2H-Pyran-4-carboxylic acid, 4-aminotetrahydro-, methyl ester (9CI) serves as a research tool in the development of new drugs and chemicals. Its unique structure and reactivity make it a promising candidate for the design and synthesis of novel therapeutic agents, potentially leading to breakthroughs in medicine.
Used in Organic Chemistry Research:
2H-Pyran-4-carboxylic acid, 4-aminotetrahydro-, methyl ester (9CI) is also utilized in organic chemistry research to explore its chemical properties and potential reactions. This helps scientists better understand the behavior of similar compounds and contributes to the advancement of organic chemistry knowledge.

InChI:InChI=1/C7H13NO3/c1-10-6(9)7(8)2-4-11-5-3-7/h2-5,8H2,1H3

Upstream product

• 67-56-1 methanol 
• 39124-20-4 4-aminotetrahydro-2H-pyran-4-carboxylic acid 
• 50289-12-8 4-amino-tetrahydro-2H-pyran-4-carbonitrile 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 

Downstream Products

• 1326318-35-7 C₁₅H₁₆BrCl₂NO₄ 
• 1326318-10-8 C₂₅H₃₀ClNO₄ 
• 1326317-99-0 C₂₇H₃₀ClNO₅ 
• 1326317-95-6 C₂₈H₃₂ClNO₄ 
• 1326317-71-8 C₂₀H₁₆Cl₃NO₃ 
• 1326317-70-7 C₂₄H₂₆ClNO₃ 
• 1326318-32-4 C₁₄H₁₂BrCl₂NO₃ 
• 720706-20-7 (4-aminotetrahydro-2H-pyran-4-yl)methanol 

Relevant articles and documents

Design and Synthesis of Fsp3-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening

The exploration of innovative chemical space is a critical step in the early phases of drug discovery. Bis-spirocyclic frameworks occur in natural products and other biologically relevant metabolites and show attractive features, such as molecular compactness, structural complexity, and three-dimensional character. A concise approach to the synthesis of bis-spirocyclic-based compound libraries starting from readily available commercial reagents and robust chemical transformations has been developed. A number of novel bis-spirocyclic scaffold examples, as implemented in the European Lead Factory project, is presented.

CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted cyclylamine derivatives as shown in formulas (1).

PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: -N(R7)-, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: -N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: -N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines

1-Isoquinolinylguanidines were previously disclosed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA). Further investigation of this template has revealed that incorporation of a 7-sulfonamide group furnishes a new series of potent and highly selective uPA inhibitors. Potency and selectivity can be achieved with sulfonamides derived from a variety of amines and is further enhanced by the incorporation of sulfonamides derived from amino acids. The binding mode of these 1-isoquinolinylguanidines has been investigated by X-ray cocrystallization studies. uPA inhibitor 26 was selected for further evaluation based on its excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). In vitro, compound 26 is able to inhibit exogenous uPA in human chronic wound fluid (IC50 = 0.89 μM). In vivo, in a porcine acute excisional wound model, following topical delivery, compound 26 is able to penetrate into pig wounds and inhibit exogenous uPA activity with no adverse effect on wound healing parameters. On the basis of this profile, compound 26 (UK-371,804) was selected as a candidate for further preclinical evaluation for the treatment of chronic dermal ulcers.

Composition for the treatment of damaged tissue

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

Isoquinolines

Isoquinolinylguanidine compounds of formula (I): STR1 wherein the substituents are as defined herein, and salts thereof, are disclosed as urokinase inhibitors.